Patent · US Active

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

US10189906B2 · kind B2 · utility

6Cited by

0References

8Claims

0Family size

Assignee

MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER · DE

Inventors

Martin Lipp · Berlin, DE
Felix Oden · Berlin, DE
Uta Höpken · Berlin, DE
Gerd Muller · Jena, DE
Oliver Daumke · Berlin, DE
Stephen Marino · Berlin, DE
Daniel Olal · Berlin, DE

Key dates

Filing date	Nov 1, 2013
Grant date	Jan 29, 2019
Priority date	—
Expiry date	Nov 1, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to antibodies or antibody fragments that bind CD269 (BCMA), thereby disrupting the interaction between CD269 and its native ligands (BAFF and APRIL), and their use in the treatment of plasma cell-mediated diseases such as multiple myeloma and autoimmune diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.